TAMPA, Fla.--(BUSINESS WIRE)--A majority-owned subsidiary of Accentia Biopharmaceuticals Inc. (NASDAQ: ABPI), Biovest International, Inc. (OTCBB: BVTI), announced that it has launched its breakthrough AutovaxID automated cell culture device for commercial sale. AutovaxID is a fully automated, reusable instrument that employs a fully disposable, closed-system cell-growth chamber incorporating a hollow-fiber cell-growth cartridge. This unique bioreactor replaces conventional stainless steel, glass, and plastic cell-growth chambers that require up to ten times as much laboratory space.
